

## DAFTAR PUSTAKA

- Abrahamson, M., Alvarez-Fernandez, M., & Nathanson, C.-M. 2003. Cystatins. *Biochemical Society Symposia*, 70, 179–199.
- Agrawal, A., Ilango, K., Singh, P. K., Karmakar, D., Singh, G. P. I., Kumari, R., & Dubey, G. P. 2015. Age dependent levels of plasma homocysteine and cognitive performance. *Behavioural Brain Research*, 283, 139–144.
- Aisara, S., Azmi, S., & Yanni, M. 2018. Gambaran Klinis penderita penyakit Ginjal Kronik Yang Menjalani hemodialisis di rsup dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, 7(1), 42.
- Antoine, V., Souid, M., André, C., Barthélémy, F., Saint-Jean, O. 2004. Symptoms and quality of life of hemodialysis patients aged 75 and over. *Nephrologie*, 25: 89–96.
- Armulik, A., Genové, G., Mäe, M., Nisancioglu, M.H., Wallgard, E., Niaudet, C., *et al.* 2010. Pericytes regulate the blood-brain barrier. *Nature*, 468, 557–561.
- Baars, B.J., & Gage, N.M. 2010. Cognition, brain, and consciousness: Introduction to cognitive neuroscience, 2nd ed. Elsevier Academic Press. ISBN: 978-0-12-375070-9
- Barrett, A.J. 1981. Cystatin, the egg white inhibitor of cysteine proteinases. *Methods Enzymol.* 80: 771–8.
- Baumgart, M., Snyder, H.M., Carrillo, M.C., Fazio, S., Kim, H., John, H. 2015. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population based perspective. *Alzheimers Dement*, 11: 718–726
- Bernelot, S.J., Verweij, S.L., van der Valk, F.M., van Capelleveen, J.C., Kroon, J., Versloot, M., *et al.* 2017. Arterial and cellular inflammation in patients with CKD. *J. Am. Soc. Nephrol*, 28, 1278–1285
- Biessels, G.J., Strachan, M.W.J., Visseren, F.L.J., Kappelle, L.J., Whitmer, R.A. 2014. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. *Lancet Diabetes Endocrinol*, 2(3):246–255.
- Bird, P. I., Trapani, J. A., and Villadangos, J. A. 2009 Endolysosomal proteases and their inhibitors in immunity. *Nat. Rev. Immunol*, 9, 871–882
- Bostom, A.G., Dworkin, L.D. 2000. Cystatin-C measurement: Improved detection of mild decrements in glomerular filtration rate versus creatinine-based estimates? *Am J Kidney Dis.* 36: 205–7.
- Bugnicourt, J.M., Godefroy, O., Chillon, J.M., Choukroun, G., Massy, Z.A. 2013. Cognitive disorders and dementia in CKD: The neglected kidney-brain axis. *J Am Soc Nephrol*, 24:353–363.
- Burns, C.M., Knopman, D.S., Tupper, D.E., Davey, C.S., Slinin, Y.M., *et al.* 2018. Prevalence and risk of severe cognitive impairment in advanced chronic kidney disease. *J Gerontol*, 73(3):393–399.
- Canavan, M. and O'Donnell, J. 2022. Hypertension and cognitive impairment: a review of mechanism and key concepts. *Frontiers in Neurology*, 13: 821135.
- Canney, M., Sexton, E., Tobin, K., Kenny, R.A., Little, M.A., O'Seaghemodialisaha, C.M. 2018. The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker. *Clinical Kidney*

- Cao, Z. and Cooper, M.E. 2011. Pathogenesis of diabetic nephropathy. *Journal of Diabetes Investigation* 2;4.
- Chawla, T., Shing, archana, & Deepika, S. (2010). Role of the renin angiotensin system in diabetic nephropathy. *World Journal of Diabetes*, 1(5), 141.
- Chen, T.K., Knicely, D.H., Grams, M.E. 2019. Chronic kidney disease diagnosis and management a review. *JAMA*,322(13):1294 -1304.
- Chen, X., Huang, Y., Bao, T., Jia, F., Ou, R., Wei, Q., et.al. 2022. Change in Serum Cystatin-C Levels and the Association with Cognitive Function in Alzheimer's Disease Patients. *Front. Aging Neurosci.* 13:790939.
- Cheng, H.M., Koutsidis, G., Lodge, J., Ashor, A., Siervo, M., Lara, J. 2017. Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis. *Atherosclerosis*, 257, 100–108.
- Chen, Y.C., Weng, S.C., Liu, J.S., Chuang, H.L., Hsu, C.C., Tarng, D.C. 2017. Severe decline of estimated glomerular filtration rate associates with progressive cognitive deterioration in the elderly: a Community-Based Cohort Study. *Sci Rep*, 7;7:1–10.
- Chou, Y., Chu, T. and Lin, S. 2018. Role of renin-angiotensin system in acute kidney injury-chronic kidney disease transition. *Nephrology* 23; 4; 121-25
- Chrabaszczewska, M., Sieradzan, A.K., Rodziewicz, S., Grubb, A., Dobson, C.M., et.al. 2020. Structural Characterization of Covalently Stabilized Human Cystatin-C Oligomers. *Int J Mol Sci*, 21(16): 5860
- Chaiben, V.B.O., Silveira, T.B.D., Guedes, M.H., Fernandes, J.P.A., Ferreira, J.H.F., Beltrao, J., et al. 2018. Cognition and renal function: findings from a Brazilian population. *J Bras Nefrol.* 41(2):200
- Collins, A.J., Foley, R.N., Herzog, C., Chavers, B., Gilbertson, D., Ishani, A., et.al. 2011. US Renal Data System 2010 Annual Data Report. *Am J Kidney Dis*, 57[Suppl 1]: A8, 1–526
- Costantino, V.V., Lorenzo, A.F., Bocanegra, V. and Valles, P.G. 2021. Molecular mechanisms of hypertensive nephropathy: renoprotective effect of losartan through Hsp70. *Cells*, 10;3146.
- Cookson., M.R. 2009. Review  $\alpha$ -Synuclein and neuronal cell death. *Molecular Neurodegeneration*. 4:9 doi:10.1186/1750-1326-4-9
- Davis, D. H. J., Creavin, S. T., Yip, J. L. Y., Noel-Storr, A. H., Brayne, C., & Cullum, S. 2015. Montreal cognitive assessment for the diagnosis of alzheimer's disease and other dementias. *Cochrane Database of Systematic Reviews*. Issue 10. Art. Z
- De Deyn, P.P., Vanholder, R., Eloot, S., Glorieux, G. 2009. Guanidino compounds as uremic (neuro) toxins. *Semin Dial*, 22: 340–345.
- Deinum, J. & Derkx, F.H. 2000. Cystatin for estimation of glomerular filtration rate? *Lancet*. 356: 1624–5.
- Dimas, A.S., Lagou, V., Barker, A., Knowles, J.W., Maggi, R., Hivert, M., et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. *Diabetes*. 2014;63(6):2158–2171.
- Drew DA, Weiner DE, Tighiouart H, Scott T, Lou K, Kantor A, et al. 2015. Cognitive

- function and all cause mortality in maintenance hemodialysis patients. *Am J Kidney Dis*, 65:303-311.
- Drew, D. A., Weiner, D. E., & Sarnak, M. J. 2019. Cognitive impairment in CKD: Pathophysiology, management, and prevention. *American Journal of Kidney Diseases*, 74(6), 782–790.
- Duron, E., Hanon, O. 2008. Vascular risk factors, cognitive decline, and dementia. *Vasc Health Risk Manag*, 4: 363–381
- Elias, M.F., Elias, P.K., Seliger, S.L., Narsipur, S.S., Dore, G.A., Robbins, M.A. 2009. Chronic kidney disease, creatinine and cognitive functioning. *Nephrol Dial Transplant*, 24: 2446–2452.
- Elobeid, A., Libard, S., Leino, M., Popova, S. N., Alafuzoff, I. (2016). Altered proteins in the aging brain. *J. Neuropathol. Exp. Neurol*, 75, 316–325.
- Fattah, H., Layton, A., Vallon, V. 2019. How Do Kidneys Adapt to a Deficit or Loss in Nephron Number? *Physiology (Bethesda)*, 01;34(3):189-197.
- Ferrario, C.M., Jessup, J.A., Smith, R.D. 2013. Hemodynamic and hormonal patterns of untreated essential hypertension in men and women. *Ther Adv Cardiovasc Dis*, 7:293-305
- Fouque, D., Kalantar-Zadeh, K., Kopple, J., Cano, N., Chauvea, P., Cuppari, L., et al. 2011. A proposed nomenclature and diagnostic criteria for protein energy wasting in acute and chronic kidney disease. *Kidney International*, 73:391- 8.
- Franco, A., Starosta, R.T., Roriz, M. 2019. The specific impact of uremic toxins upon cognitive domains: a review. *Braz. J. Nephrol*, 41(1):103-111.
- Gage, N., Roberts, T.P., Hickok, G. 2006. Temporal resolution properties of human auditory cortex: Reflections in the neuromagnetic auditory evoked m100 component. *Brain Research*, 1069 ( 1 ), 166 – 171
- Gauthier, S., Kaur, G., Mi, W., Tizon, B. & Levy, E. 2011. Protective mechanisms by cystatin-C in neurodegenerative diseases. *Front. Biosci (Schol Ed)*, 3, 541–554.
- GBD Chronic Kidney Disease Collaboration. 2020. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. *Lancet*. 395:709–33
- Gela, Y. Y., Getu, A. A., Adane, A., Ayal, B. M., Akalu, Y., Diress, M., et al. 2021. Cognitive impairment and associated factors among chronic kidney disease patients: a comparative cross-sectional study. *Neuropsychiatric Disease and Treatment*, 17: 1483-1492.
- Gesualdo, G.D., Duarte, J.G., Zazzetta, M.S., Kusumota, L., Say, K.G., Pavarini, S., et al. 2017. Cognitive impairment of patients with chronic renal disease on hemodialysis and its relationship with sociodemographic and clinical characteristics. *Dement Neuropsychol*, 11(3):221–226.
- Glasscock, R.J. 2008. Uremic toxins: what are they? an integrated overview of pathobiology and classification. *J. Ren. Nutr*, 18, 2–6.
- Goldstein, E.B. 2011. Cognitive Psychology : Connecting Mind, Research, And Everyday Experience. Third Edition. *Wadsworth Cengage Learning*.
- Goldstein, F.C, Levey, A.I, Steenland, N.K. 2013. High blood pressure and cognitive decline in mild cognitive impairment. *J Am Geriatr Soc*, 61(1):67–73.



- Gryp, T., Vanholder, R., Vaneechoutte, M., and Glorieux, G. 2017. p-Cresyl Sulfate. *Toxins*, 9:52.
- Gupta, J., Mitra, N., Kanetsky, P.A., Devaney, J., Wing, M.R., Reilly, M., *et al.* 2012. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. *Clin. J. Am. Soc. Nephrol*, 7, 1938–1946.
- Hailpern, S.M., Melamed, M.L., Cohen, H.W., Hostetter, T.H. 2007. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). *J Am Soc Nephrol*, 18: 2205–2213.
- Hajjar, I., Goldstein, F.C., Martin, G.S., Quyyumi, A.A. 2016. Roles of arterial stiffness and blood pressure in hypertension-associated cognitive decline in healthy adults. *Hypertension*, 67(1):171–175.
- Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S.H., *et al.* 2021. The Amyloid- $\beta$  Pathway in Alzheimer's Disease. *Molecular Psychiatry*, 26:5481–5503
- Harvey PD. 2019. Domains of cognition and their assessment. *Dialogues Clin Neurosci*, 21(3):227-237. doi:10.31887/DCNS.2019.21.3/pharvey.
- Helmer, C., Stengel, B., Metzger, M., Froissart, M., Massy, Z.A., Tzourio, C., *et al.* 2011. Chronic kidney disease, cognitive decline, and incident dementia: The 3C Study. *Neurology*, 77: 2043–2051.
- Hering, L., Rahman, M., Potthoff, S., Rump, L., & Stegbauer, J. 2020. Role of  $\alpha$ 2-adrenoceptors in hypertension: Focus on renal sympathetic neurotransmitter release, inflammation, and sodium homeostasis. *Frontiers in Physiology*, 11.
- Hermann, D.M., Kribben, A., Bruck, H. 2014. Cognitive impairment in chronic kidney disease: clinical findings, risk factors and consequences for patient care. *J Neural Transm*, 121(6):627–632.
- Iadecola, C. 2013. The pathobiology of vascular dementia. *Neuron* 80, 844–866.
- Iadecola C., Yaffe K., Biller J., Bratzke LC., Faraci FM., *et al.* 2016. Impact of Hypertension on Cognitive Function A Scientific Statement From the American Heart Association. *ahajournals.org*, 68.
- Indonesia Renal Registry (IRR). 2018. 11<sup>th</sup> Report Of Indonesian Renal Registry 2018.
- Ito, S., Osaka, M., Higuchi, Y., Nishijima, F., Ishii, H., and Yoshida, M. 2010. Indoxyl sulfate induces leukocyte-endothelial interactions through upregulation of E-selectin. *J. Biol. Chem.*, 285, 38869–38875.
- Janota, C., Lemere, C.A., Brito, M.A. 2015. Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease. *Mol. Neurobiol*, 53, 3793–3811.
- Janowski, R., Kozak, M., Jankowska, E., Grzonka, Z., Grubb, A., Abrahamson, M., *et al.* 2001. Human cystatin-C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. *Nature Struct Biol*, 8: 316–20.
- Kalantar, Z.K., Jafar, T.H., Nitsch, D., Neuen, B.L., Perkovic, V. 2021. Chronic kidney disease. *Lancet*. 28;398:786–802.
- Kandlur, A., Satyamoorthy, K., Gangadharan, G. 2020. Oxidative Stress in Cognitive and Epigenetic Aging: A Retrospective Glance. *Front. Mol. Neurosci*, 13:41
- Kemenkes RI. 2018. Laporan Hasil Riset Kesehatan Dasar (Riskesdas) Indonesia tahun

2018. Riset Kesehatan Dasar 2018, 171-176
- Kestenbaum, B., Rudser, K. D., de Boer, I. H., Peralta, C. A., Fried, L. F., Shlipak, M. G., et al. 2008. Differences in kidney function and incident hypertension: The multi-ethnic study of Atherosclerosis. *Annals of Internal Medicine*, 148(7), 501- 508.
- Kim, J., Kim, H., Roh, H., and Kwon, Y. 2018. Causes of hyperhomocysteinemia and its pathological significance. *Arch. Pharm. Res*, 41, 372–383.
- Kolodziejczyk, R., Michalska, K., Hernandez, S.A., Whalbm, M., Grubb, A., Jhakolski, M. 2010. Crystal structure of human cystatin-C stabilized against amyloid formation. *Febs J.*, 277, 1726–1737
- Kurella, M., Yaffe, K., Shlipak, M. G., Wenger, N. K., & Chertow, G. M. (2005). Chronic kidney disease and cognitive impairment in Menopausal women. *American Journal of Kidney Diseases*, 45(1), 66–76.
- Kurella, M., Mapes, D.L., Port, F.K., Chertow, G.M. 2006. Correlates and outcomes of dementia among dialysis patients: The Dialysis Outcomes and Practice Patterns Study. *Nephrol Dial Transplant*, 21: 2543–2548
- Lee, S., Buring, J.E., Cook, N.R., Grodstein, F. 2006. The relation of education and income to cognitive function among professional women. *Neuroepidemiology*, 26(2):93–101.
- Legdeur, N., Heymans, M.W., Comijs, H.C., Huisman, M., Maier, A.B., Visser, P.J. 2018. Age dependency of risk factors for cognitive decline. *BMC Geriatry*, 18(1):1–10.
- Levey, A.S. & Inker, L.A. 2017. Assessment of glomerular filtration rate in health and disease: a state of the art review. *Clin Pharmacol Ther*, 102:405–419.
- Levy, E., Jaskolski, M., Grubb, A. 2006. The role of cystatin-C in cerebral amyloid angiopathy and stroke: cell biology and animal models. *Brain Pathol*, 16, 60-70.
- Levy, E., Kaur, G. 2012. cystatin-C in Alzheimer's Disease. *Frontiers in Molecular Neuroscience*, 5 (79), 1-17
- Lezak, M.D., Howieson, D.B., Bigler, E.D., Tranel, D. 2011. Neuropsychological Assessment. 5th ed. Oxford, UK; New York, NY: Oxford University Press.
- Liao, J.K. 2013. Linking endothelial dysfunction with endothelial cell activation. *J. Clin. Investig*, 123, 540–541
- Lin, C., Liu, H., Lin, S. 2021. Kidney Function and Risk of Physical and Cognitive Impairment in Older Persons with Type 2 Diabetes at an Outpatient Clinic with Geriatric Assessment Implementation. *Dovepress*, 15 79–91.
- Lin SF, Fan YC, Kuo TT, Pan WH, Bai CH. 2022. Quality of life and cognitive assessment in healthy older Asian people with early and moderate chronic kidney disease: The NAHSIT 2013–2016 and validation study. *PLoS ONE* 17(3)
- Lutz J., Menke J., Sollinger D., Schinzel H., Thrumel K. 2014. Haemostasis in chronic kidney disease. *Nephrol Dial Transplant*, 29:29–40.
- Lutgens, S.P.M., Cleutjens, K.B.J.M., Daemen, M., Heeneman, S. 2007. Cathepsin cysteine proteases in cardiovascular disease. *FASEB J*, 21, 3029–3041
- Lyu J., Kim HY. 2016. Gender-Specific Incidence and Predictors of Cognitive

- Impairment among Older Koreans: Findings from a 6-Year Prospective Cohort Study. *Psychiatry Investig*, 13(5):473-479
- Maciel, R.A., Cunha, R.S., Busato, V., Franco, C.R.C., Gregório, P.C., Dolenga, C.J.R., *et al.* 2018. Uremia impacts ve-cadherin and zo-1 expression in human endothelial cell-to-cell junctions. *Toxins*, 10, 1–22.
- Madero M, Sarnak MJ, Stevens LA. 2006. Serum cystatin-C as a marker of glomerular filtration rate. *Curr Opin Nephrol Hypertens*. 15:610–616.
- Madero M, Gul A, Sarnak MJ.2008. Cognitive function in chronic kidney disease. *Semin Dial* 21: 29–37.
- Maetzler W, Schimid B, Synofzik M, Schulte C, Riester K, Huber H. *et. Al.* 2010. The CST3 BB genotype and low cystatin-C cerebrospinal fluid levels are associated with dementia in Lewy body disease. *J. Alzheimer Dis*. 19, 937-942,
- Maheshwari, K. U., Santhi, S., & Malar, R. J. 2015. Cystatin C: An alternative dialysis adequacy marker in high flux hemodialysis. *Indian Journal of Nephrology*, 25(3), 143.
- Mathews PM. & Levy, E. 2016. Cystatin-C in aging and in Alzheimer’s disease. *Ageing Res. Rev.* 32: 38–50.
- Matovinovic, M.S. 2009. Pathophysiology and classification of kidney disease. *eJIFCC*, 20;1.
- Mennuni, S., Rubattu, S., Pierelli, G., Tocci, G., Fofi, C. and Volpe, M. 2014. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. *Journal of Human Hypertension*, 28 : 74-79.
- Mogi, M., Horiuchi, M. 2011. Clinical interaction between brain and kidney in small vessel disease. *Cardiol Res Pract*, 306189
- Murray, A.M., Tupper, D.E., Knopman, D.S., *et al.* 2006. Cognitive impairment in hemodialysis patients is common. *Neurology*, 67(2):216–223
- Mussap, M., Plebani, M. 2004. Biochemistry and Clinical Role of Human Cystatin-C in Critical Reviews in Clinical Laboratory Sciences. *Taylor & Francis*, 5-6 (41) 467-550.
- National Kidney Foundation. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplements*. 2013.
- Newman DJ.2002. 'Cystatin-C', in *Annals of clinical biochemistry*. vol 39, 89-104.
- Nunns, G.R., Moore, E.E., Chapman, M.P., Moore, H.B., Stettler, G.R., Peltz, E., *et.al.* 2017. The Hypercoagulability Paradox of Chronic Kidney Disease: The Role of Fibrinogen. *Am J Surg*. 214(6): 1215–1218.
- O’Brien, J.T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., *et.al.*2003. Vascular cognitive impairment. *Lancet Neurol*, 2: 89–98.
- Ogliari, G., Sabayan, B., Mari, D., Rossi, P.D., Lucchi, T.A., Craen, A., *et al.*2015. Age- and functional status– dependent association between blood pressure and cognition: the milan geriatrics 75+ cohort study. *J Am Geriatr Soc*, 63 (9):1741–1748.
- Palm, F. & Nordquist, L. 2011. Renal oxidative stress, oxygenation, and hypertension. *Am J Physiol*, 301; 229-41.



- Paul, C.M., Rogelio, L., & Laura, C.B. 2014. Amyloid Beta: Multiple Mechanisms of Toxicity and Only Some Protective Effects?. *Hindawi Publishing Corporation Oxidative Medicine and Cellular Longevity*, 2014, 1-15.
- Pantoni, L. 2010. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol*, 9(7):689–701.
- Pei, X., Lai, S., He, X., Masembe, N. P., Yuan, H., Yong, Z, et al. 2019. Mild cognitive impairment in maintenance hemodialysis patients: a cross-sectional survey and cohort study. *Clinical Interventions in Aging*, 14 : 27 – 32.
- Parisi, J. M., Rebok, G. W., Xue, Q.-L., Fried, L. P., Seeman, T. E., Tanner, E. K., et al. 2012. The role of education and intellectual activity on cognition. *Journal of Aging Research*, 2012, 1–9.
- Pendlebury, S.T., Cuthbertson, F.C., Welch, S., Mehta, Z., Rothwell, P.M. 2010. Underestimation of Cognitive Impairment by Mini Mental State Examination versus the Montreal Cognitive Assessment in patients with Transient Ischemic Attack and Stroke. *A population based study*, 41:1290
- Peralta, C.A., Shlipak, M.G., Judd, S., Cushman, M., McClellan, W., Zakai, N.A., et al. 2011. Detection of chronic kidney disease with creatinine, cystatin-C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. *Journal of the American Medical Association*, 305 (15):1545–52.
- Peters, R. 2006. Ageing and the brain. *Postgrad. Med.*, J. 82, 84–88.
- PERDOSSI. 2015. Panduan Praktik Klinik Diagnosis Dan Penatalaksanaan Demensia. Jakarta Pusat, perdossi.
- Pérez, G., Sahoo, S., Gauthier, S., Kim, Y., Li, M., Kumar, A., et al. 2019. Neuroprotection mediated by cystatin-C-loaded extracellular vesicles. *Scientific Reports*. 9:11104.
- Perna, A.F., Ingrosso, D., Satta, E., Lombardi, C., Galletti, P., D’Aniello, A., et al. 2004. Plasma protein aspartyl damage is increased in hemodialysis patients: Studies on causes and consequences. *J Am Soc Nephrol*, 15: 2747– 2754.
- Rakowski, D., Caillard, S., Agodoa, L., Abbott, K. 2006. Dementia as a predictor of mortality in dialysis patients. *Clin J Am Soc Nephrol*, 1(5): 1000-5
- Raman, M., Middleton, R.J., Kalra, P.A., Green, D., 2017. Estimating renal function in old people: an in-depth review. *Int. Urol. Nephrol*, 49, 1979-1988.
- Rapa, F. S., Lorio, B.R., Campiglia, P., Heriland, A. and Marzocco, S. 2019. *Int J Mol Sci*, 21; 263.
- Raphael, K., Wei, G., Greene, T., Baird, B., Beddhu, S.2012. Cognitive function and the risk of death in chronic kidney disease. *Am J Nephrol*, 35(1):49-57
- Rempel, L.C.T., Finco, A.B., Maciel, R.A., Bosquetti, B., Alvarenga, L.M., Souza, W.M., et al. 2015. Effect of PKC-β signaling pathway on expression of MCP-1 and VCAM-1 in different cell models in response to advanced glycation end products (AGEs). *Toxins*, 7, 1722–1737.
- Reed, B.R., Mungas, D.M., Kramer, J.H., Ellis, W., Vinters, H.V., Zarow, C. 2007. Profiles of neuropsychological impairment in autopsy-defined Alzheimer’s disease and cerebrovascular disease. *Brain*, 130: 731– 739.

- Risch, L., Huber, A.R. 2002. Assessing the diagnostic accuracy of cystatin-C as a marker of impaired glomerular filtration rate. *Am J Kidney Dis*. 39: 661–2.
- Roberts, R.O., Knopman, D.S., Geda, Y.E., Cha, R.H., Pankratz, V.S., Baertlein, L., et al. 2014. Association of diabetes with amnesic and nonamnesic mild cognitive impairment. *Alzheimers Dement*, 10(1):18–26
- Romero, J.R., Beiser, A., Seshadri, S., Benjamin, E.J., Polak, J.F., Vasan, R.S. 2009. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: The Framingham study. *Stroke*, 40: 1590–1596.
- Rosner, M.H., Reis, T., Husain-Syed, Vanholder, R., Hutchison, C., Stenvinkel, P., et.al. 2021. Classification of Uremic Toxins and Their Role in Kidney Failure. *CJASN*, 16: 1918–1928
- Ryan, J.P., Fine, D.F., Rosano, C. 2014. Type 2 diabetes and cognitive impairment: contributions from neuroimaging. *J Geriatr Psychiatry Neurol*, 27(1):47–55.
- Sarnak, M.J., Tighiouart, H., Scott, T.M. 2013. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. *Neurology*, 80(5):471–480.
- Sacre, J.W., Magliano, D.J., Zimmet, P.Z., Polkinghorne, K.R., Chadbang, S.J, Anstey, K.J., et.al. 2019. Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study. *Journal of Alzheimer's Disease*, 70. S19–S30.
- Sastre, M., Calero, M., Pawlik, M., Kumar, A., Danilov, V., et al. 2004. Binding of cystatin-C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. *Neurobiol Aging*, 25:1033–1043.
- Scioli, M.G., Storti, G., D'Amico, F., Guzman, R.R., Centovanti, F., Doldo, E., et al. 2020. Oxidative stress and New Pathogenetic Mechanisms in Endothelial Dysfunction : Potential Diagnostic Biomarkers and Therapeutic Targets. *J. Clin. Med.* 9,1995.
- Seliger, S.L., Siscovick, D.S., Stehman-Breen, C.O., Gillen, D.L., Fitzpatrick, A., Bleyer, A., et al. 2004. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. *J Am Soc Nephrol*, 15:1904–1911.
- Sena, C.M., Leandro, A., Azul, L., Seica, R. and Perry, G. 2018. Vascular oxidative stress: impact and therapeutic approaches. *Frontiers in Physiology*, 9: 1668.
- Seifter, J.L. & Samuels, M.A. 2011. Uremic encephalopathy and other brain disorders associated with renal failure. *Semin Neurol*, 31: 139–143.
- Shamsi, A. & Bano, B. 2017. Journey of cystatins from being mere thiol protease inhibitors to at heart of many pathological conditions. *International journal of biological macromolecules*, 102, 674–693.
- Shang, S., Li, P., Deng, M., Jiang, Y., Chen, C., Qu, Q. 2016. The age-dependent relationship between blood pressure and cognitive impairment: a cross-sectional study in a rural area of Xi'an, China. *PLoS One*, 11(7)
- Sheikh, A.M., Wada, Y., Tabassum, S., Inagaki, S., Mitaki, S., Yano, S., et.al. 2021. Aggregation of cystatin-C Changes Its Inhibitory Functions on Protease Activities and Amyloid Fibril Formation. *Int. J. Mol. Sci.*, 22, 9682
- Shlipak, M. G., Matsushita, K., Ärnlöv, J., Inker, L. A., Katz, R., Polkinghorne, K. R.,



- et.al. 2013. Cystatin-C versus creatinine in determining risk based on kidney function. *N. Engl. J. Med.* 369, 932–943
- Shimokawa, H. 2014. Williams Harvey Lecture: Importance of coronary vasomotion abnormalities—from bench to bedside. *Eur. Heart J.* 35, 3180–3193.
- Sidenkova, A., Litvinenki, V. and Kalinin, I. 2020. The mechanisms of the protective effect of education in cognitive aging. *BIO Web of Conferences*, 22 : 01016.
- Silvestrini, M, Pasqualetti, P., Baruffaldi, R., Bartolini, M., Handouk, Y., Matteis, M., et.al. 2006. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. *Stroke*, 37: 1010–1015
- Slinin, Y., Paudel, M.L., Ishani, A., Taylor, B.C., Yaffe, K., Murray, A.M., et al. 2008. Kidney function and cognitive performance and decline in older men. *J Am Geriatr Soc.*, 56:2082–2088.
- Smeltzer, Suzanne, C., & Brenda, G.B. 2001. Buku Ajar Keperawatan Medikal Bedah Brunner & Suddarth. Edisi 8. Jakarta :EGC.
- Smith, E. R. 2013. Cystatin-C. More than a filtration marker. *Atherosclerosis*, 230, 73–75
- Straface, E., Matarrese, P., Gambardella, L., Vona, R., Sgadari, A., Silveri, M. C., et al. 2005. Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study. *FEBS Lett*, 579, 2759–2766.
- Stefani, A., Sancesario, G., Pierantozzi, M., Leone, G., Galati, S., Hainsworth, A.H., et al. 2009. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. *J Neurol Sci*, 283: 109–115
- Stevens, L.A., Coresh, J., Greene, T., Levey, A.S. 2006. Assessing kidney function measured and estimated glomerular filtration rate. *The New England journal of medicine*, 354(23):2473–83.
- Stinghen, A.E., Pecoits-Filho, R. 2011. Vascular damage in kidney disease.2011. Beyond hypertension. *Int J Hypertens*, 232683.
- Sundelof, J., Sundstrom, J., Hansson, O., Eriksson, M., Giedraitis, V., Larsson, A., et al. 2010. cystatin-C Levels are Positively Correlated with both A-Beta 42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. *J Alzheimers Dis.*, 21:471–478.
- Suyono & Slamet. 2001. Buku Ajar Ilmu Penyakit Dalam. Edisi 3. Jilid I II. Jakarta.: Balai Penerbit FKUI.
- Suzuki, Y., Jin, C., Yazawa, I. 2014. cystatin-C Triggers Neuronal Degeneration in a Model of Multiple System Atrophy. *The American Journal of Pathology*, 184 (3),790-799.
- Tamadon, M.R., Adibimehr, A.R., Ghorbani, R. 2017. Cognitive Impairment in Dialysis and Non-Dialysis Patients Suffffering from Chronic Renal Failure and Comparing Them with a Control Group. *Middle East J Rehabil Health Stud.*, 4(4):e12815.
- Tamura, M.K., Wadley, V., Yaffe, K., McClure, L.A., Howard, G., Go, R., et al. 2008. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Am J Kidney Dis.*, 52:227–234.

- Tangri, N., Inker, L.A., Tighiouart, H., Sorensen, E., Menon, V., Beck, G., *et al.* 2012. Filtration markers may have prognostic value independent of glomerular filtration rate. *J Am Soc Nephrol*, 23:351–359.
- Thancharoen, O., Waleekhachonloet, O., Limwattananon, C., Anutrakulchai, S. 2020. Cognitive impairment, quality of life and healthcare utilization in patients with chronic kidney disease stages 3 to 5. *Nephrology*, Wiley, 1–9
- Tizon, B., Ribe, E.M., Mi, W., Troy, C.M., Levy, E. 2010. cystatin-C protects neuronal cells from amyloid-beta-induced toxicity. *J Alzheimers Dis.*, 19:885–894.
- Uddin, M. S., Stachowiak, A., Mamun, A., Al Tzvetkov, N. T., Takeda, S., Atanasov, A. G., *et al.* 2018. Autophagy and Alzheimer’s Disease: from molecular mechanisms to therapeutic implications. *Front. Aging Neurosci*, 10:4.
- Umegaki, H., Kawamura, T., Umemura, T., Kawano, N. 2015. Factors associated with cognitive decline in older adults with type 2 diabetes mellitus during a 6-year observation. *Geriatr Gerontol Int.*, 15 (3):302–310.
- Vanhoutte, P.M., Shimokawa, H., Feletou, M., Tang, E.H.C. 2017. Endothelial dysfunction and vascular disease—a 30<sup>th</sup> anniversary update. *Acta Physiol.*, 219, 22–96.
- Veld, B.A., Ruitenber, A., Hofman, A., Stricker, B.H., Breteler, M.M. 2001. Antihypertensive drugs and incidence of dementia: The Rotterdam Study. *Neurobiol Aging*, 22: 407– 412
- Vermeer, S.E., Prins, N.D., den Heijer, T., Hofman, A., Koudstaal, P.J., Breteler, M.M. 2003. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl Jmed*, 348: 1215–1222
- Vetrivel, K.S. & Thinakaran, G. 2006. Amyloidogenic processing of  $\beta$ -amyloid precursor protein in intracellular compartments,” *Neurology*, vol. 66, no. 2, pp. S69–S73.
- Viggiano, D., Wagner, C.A., Blankestijn, P.J., Bruchfeld, A., Fliser, D., Fouque, D., *et al.* 2020. Mild cognitive impairment and kidney disease: clinical aspects. *Nephrol Dial Transplant*, 35: 10–17
- Vos, T., Bikbov, B. 2020. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Elsevier*, 709-733
- Wang, H., Fang, C., Cai, L., Dong, B., Deng, J. 2016. Chronic kidney disease and cognitive impairment among the very old in China. *Aging Clin Exp Res.*, 28(3):475–482.
- Wang, R., Chen, Z., Fu, Y., Wei, X., Liao, J., Liu, X., *et al.* 2017. Plasma cystatin-C and high-density lipoprotein are important biomarkers of Alzheimer’s disease and vascular dementia: a cross-sectional study. *Front. Aging Neurosci.* 9, 26.
- Watanabe, K., Watanabe, T., Nakayama, M. 2014. Cerebro-renal interactions: impact of uremic toxins on cognitive function. *Neurotoxicology*, 44:184–93.
- Whissell, C., Charles, I., Abramson, Barber, K.R. 2013. The Search for Cognitive Terminology: An Analysis of Comparative Psychology Journal Titles. *Behav. Sci.*, 2013, 3, 133–142
- Xin, S., Panpan, L., Hanhan, L., & Verena, P. 2022. Oxidative Stress, Vascular

- Endothelium, and the Pathology of Neurodegeneration in Retina. *Antioxidants*, 2022, 11, 543
- Yaffe, K., Ackerson, L., Kurella, T.M., Le Blanc, P., Kusek, J.W., Sehgal, A.R., et.al. 2010. Chronic Renal Insufficiency Cohort Investigators: Chronic kidney disease and cognitive function in older adults: Findings from the chronic renal insufficiency cohort cognitive study. *J Am Geriatr Soc*, 58: 338–345.
- Yaffe, K., Kurella, T.M., Ackerson, L., Hoang, T.D., Anderson, A.H., et al. 2014. Higher Levels of cystatin-C are Associated with Worse Cognitive Function Among Older Adults with Chronic Kidney Disease: The CRIC COG Study. *J Am Geriatr Soc.*; 62(9): 1623–1629.
- Yaffe, K., Lindquist, K., Shlipak, M.G., Simonsick, E., Fried, L., Rosano, C., et.al. 2008. cystatin-C as a marker of cognitive function in elders: Findings from the health ABC study. *Ann Neurol*, 63: 798–802.
- Yvette, C.W., Dimitri, K. 2017.  $\alpha$ -synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies .Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. *Nat Med.*, 23(2): 1–13.
- Zhang, C. Y., He, F., Su, H., Zhang, C. and Meng, X. F. 2020. Association between chronic kidney disease and Alzheimer’s disease: an update. *Metabolic Brain Disease*, 35: 883-894.
- Zheng, T., Qin, L., Chen, B., Hu, X., Zhang, X., Liu, Y., et al. 2016. Association of plasma DPP4 activity with mild cognitive impairment in elderly patients with type2 diabetes: results from the GDMD study in China. *Diabetes Care*, 39(9):1594– 1601.
- Zhong, X. M., Hou, L., Luo, X. N., Shi, H. S., Hu, G. Y., He, H. B., et al. 2013. Alterations of CSF cystatin C levels and their correlations with CSF A $\beta$ 40 and A $\beta$ 42 levels in patients with Alzheimer’s disease, dementia with lewy bodies and the atrophic form of general paresis. *PLoS ONE*, 8, e55328
- Zijlstra, L., Trompet, S., Mooijaart, S.P., Buren, M.V., Sattar, N., et al. 2020. The association of kidney function and cognitive decline in older patients at risk of cardiovascular disease: a longitudinal data analysis. *BMC Nephrology*, 21:81
- Zyga, S., Christopoulou, G., Malliarou, M. 2011. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease. *Journal of RenalCare*, 37(1), 12-15.